Ensysce Biosciences, Inc.

NasdaqCM:ENSC Stock Report

Market Cap: US$5.9m

Ensysce Biosciences Balance Sheet Health

Financial Health criteria checks 2/6

Ensysce Biosciences has a total shareholder equity of $-651.3K and total debt of $854.7K, which brings its debt-to-equity ratio to -131.2%. Its total assets and total liabilities are $2.7M and $3.4M respectively.

Key information

-131.2%

Debt to equity ratio

US$854.70k

Debt

Interest coverage ration/a
CashUS$1.12m
Equity-US$651.27k
Total liabilitiesUS$3.36m
Total assetsUS$2.71m

Recent financial health updates

Recent updates

Ensysce Biosciences secures $8M convertible note financing

Jul 01

Ensysce Biosciences: Developing New Class Of Tamper-Proof Powerful Opioids

Dec 18

Financial Position Analysis

Short Term Liabilities: ENSC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ENSC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ENSC has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ENSC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ENSC has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: ENSC is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.